Advertisement

 

 

In vitro and in vivo characterization of an interleukin-15 antagonist peptide by metabolic stability, Tc-labeling, and biological activity assays.

In vitro and in vivo characterization of an interleukin-15 antagonist peptide by metabolic stability,  Tc-labeling, and biological activity assays.
Author Information (click to view)

Rodríguez-Álvarez Y, Cabrales-Rico A, Perera-Pintado A, Prats-Capote A, Garay-Pérez HE, Reyes-Acosta O, Pérez-García E, Chico-Capote A, Santos-Savio A,


Rodríguez-Álvarez Y, Cabrales-Rico A, Perera-Pintado A, Prats-Capote A, Garay-Pérez HE, Reyes-Acosta O, Pérez-García E, Chico-Capote A, Santos-Savio A, (click to view)

Rodríguez-Álvarez Y, Cabrales-Rico A, Perera-Pintado A, Prats-Capote A, Garay-Pérez HE, Reyes-Acosta O, Pérez-García E, Chico-Capote A, Santos-Savio A,

Advertisement

Journal of peptide science : an official publication of the European Peptide Society 2018 04 15() e3078 doi 10.1002/psc.3078
Abstract

Interleukin (IL)-15 is an inflammatory cytokine that constitutes a validated therapeutic target in some immunopathologies, including rheumatoid arthritis (RA). Previously, we identified an IL-15 antagonist peptide named [K6T]P8, with potential therapeutic application in RA. In the current work, the metabolic stability of this peptide in synovial fluids from RA patients was studied. Moreover, [K6T]P8 peptide was labeled with Tc to investigate its stability in human plasma and its biodistribution pattern in healthy rats. The biological activity of [K6T]P8 peptide and its dimer was evaluated in CTLL-2 cells, using 3 different additives to improve the solubility of these peptides. The half-life of [K6T]P8 in human synovial fluid was 5.88 ± 1.73 minutes, and the major chemical modifications included peptide dimerization, cysteinylation, and methionine oxidation. Radiolabeling of [K6T]P8 with Tc showed a yield of approximately 99.8%. The Tc-labeled peptide was stable in a 30-fold molar excess of cysteine and in human plasma, displaying a low affinity to plasma proteins. Preliminary biodistribution studies in healthy Wistar rats suggested a slow elimination of the peptide through the renal and hepatic pathways. Although citric acid, sucrose, and Tween 80 enhanced the solubility of [K6T]P8 peptide and its dimer, only the sucrose did not interfere with the in vitro proliferation assay used to assess their biological activity. The results here presented, reinforce nonclinical characterization of the [K6T]P8 peptide, a potential agent for the treatment of RA and other diseases associated with IL-15 overexpression.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen + 11 =

[ HIDE/SHOW ]